ArticleMarine drugs2026
The Marine-Derived Cyclopentapeptide Turnagainolide B Suppresses Melanoma via Autophagic Flux Disruption and Inhibits Tumorigenesis In Vivo.
Guoyue Wan, Keyu Zhao, Min Wang, Ren-He Xu, Meiling Jin, Liwei Liu
Abstract read
In one paragraphArticle in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Guoyue WanCenter of Reproduction, Development & Aging, Cancer Center and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China.ORCID 0000-0002-3064-5825 Keyu ZhaoDepartment of Dermatology, The First Affiliated Hospital of Ningbo University, Ningbo 315010, China.ORCID 0000-0002-6497-4117 Min WangCollege of New Materials and Chemical Engineering, Beijing Institute of Petrochemical Technology, Beijing 102617, China.
Ren-He XuCenter of Reproduction, Development & Aging, Cancer Center and Institute of Translational Medicine, Faculty of Health Sciences, University of Macau, Taipa, Macau 999078, China.
Meiling JinState Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518000, China.
Liwei LiuLi Dak Sum Yip Yio Chin Kenneth Li Marine Biopharmaceutical Research Center, Health Science Center, Ningbo University, Ningbo 315211, China.ORCID 0000-0002-0578-1091 Funding
National Key Research and Development Program of China 2021YFA0911700National Natural Science Foundation of China 31600016Ningbo Major Research and Development Plan Project 2024Z228Ningbo Public Welfare Science and Technology Foundation 2024S175Zhejiang Provincial Medical and Health Science and Technology Project 2025HY0967Zhejiang Provincial Medical and Health Science and Technology Project 2025KY1338
6 · The paper itselfAbstract
Melanoma remains highly lethal with frequent resistance to current therapies. Here we identify a marine-derived cyclopentapeptide, turnagainolide B, as a potent anti-melanoma agent that selectively kills B16-F10 melanoma cells (IC
Indexed as
CarcinogenesisDepsipeptidesMelanoma, ExperimentalAnimalsAntineoplastic AgentsAquatic OrganismsCell Line, TumorCell SurvivalHumansMicePhosphatidylinositol 3-KinasesAntineoplastic AgentsDepsipeptidesPhosphatidylinositol 3-Kinasesturnagainolide Bautophagybioactivemarine natural productmelanomatumorigenesisturnagainolide B
Identifiers
PMID42505975
PMCPMC13412985
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390